| 000 | 01859 a2200553 4500 | ||
|---|---|---|---|
| 005 | 20250518002042.0 | ||
| 264 | 0 | _c20181122 | |
| 008 | 201811s 0 0 eng d | ||
| 022 | _a2352-3026 | ||
| 024 | 7 |
_a10.1016/S2352-3026(18)30153-4 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLocatelli, Franco | |
| 245 | 0 | 0 |
_aBrentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study. _h[electronic resource] |
| 260 |
_bThe Lancet. Haematology _cOct 2018 |
||
| 300 |
_ae450-e461 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aBrentuximab Vedotin |
| 650 | 0 | 4 | _aChild |
| 650 | 0 | 4 | _aChild, Preschool |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHodgkin Disease _xdrug therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunoconjugates _xtherapeutic use |
| 650 | 0 | 4 |
_aLymphoma, Large-Cell, Anaplastic _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aRecurrence |
| 700 | 1 | _aMauz-Koerholz, Christine | |
| 700 | 1 | _aNeville, Kathleen | |
| 700 | 1 | _aLlort, Anna | |
| 700 | 1 | _aBeishuizen, Auke | |
| 700 | 1 | _aDaw, Stephen | |
| 700 | 1 | _aPillon, Marta | |
| 700 | 1 | _aAladjidi, Nathalie | |
| 700 | 1 | _aKlingebiel, Thomas | |
| 700 | 1 | _aLandman-Parker, Judith | |
| 700 | 1 | _aMedina-Sanson, Aurora | |
| 700 | 1 | _aAugust, Keith | |
| 700 | 1 | _aSachs, Jessica | |
| 700 | 1 | _aHoffman, Kristen | |
| 700 | 1 | _aKinley, Judith | |
| 700 | 1 | _aSong, Sam | |
| 700 | 1 | _aSong, Gregory | |
| 700 | 1 | _aZhang, Stephen | |
| 700 | 1 | _aSuri, Ajit | |
| 700 | 1 | _aGore, Lia | |
| 773 | 0 |
_tThe Lancet. Haematology _gvol. 5 _gno. 10 _gp. e450-e461 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/S2352-3026(18)30153-4 _zAvailable from publisher's website |
| 999 |
_c28909434 _d28909434 |
||